R. Degier et al., A SEQUENTIAL STUDY OF INTRAVENOUS AND ORAL FLEROXACIN FOR 7 OR 14 DAYS IN THE TREATMENT OF COMPLICATED URINARY-TRACT INFECTIONS, International journal of antimicrobial agents, 6(1), 1995, pp. 27-30
Objective: To compare 1 and 2-weeks of sequential intravenous and oral
treatment for complicated urinary tract infection. Design: Randomized
, clinical trial. Setting: 2 secondary and 1 tertiary care hospital in
the Netherlands. Patients. Patients (54) were randomly assigned, afte
r 3 days Fleroxacin 400 mg iv once daily, to receive oral fleroxacin (
400 mg OD,) either during 4 (total 7) days (n = 26), or during 11 (tot
al 14) days (n = 28). Thirty-four patients were evaluable for efficacy
. Complicated urinary tract infection was defined as the presence of a
n anatomical or functional abnormality of the urinary tract, urinary t
ract instrumentation, patients presenting with clinical signs and symp
toms of pyelonephritis or a serious illness such as diabetes mellitus,
immunosuppression or renal failure. Complicated urinary tract infecti
on was defined as the presence of an anatomical or functional abnormal
ity of the urinary tract, urinary tract instrumentation, patients pres
enting with clinical signs and symptoms of pyelonephritis or a serious
illness such as diabetes mellitus, immunosuppression or renal failure
. Results: A bacteriological cure was seen in 22 of 34 (65%) patients
at 4-6 weeks after therapy. Overall, a favorable bacteriological respo
nse was obtained in 26 of 34 (76%) patients. No significant difference
could be found among the two dosage groups (7 days: 14/18 = 78%; 14 d
ays: 12/16 = 75%). Conclusions. Sequential iv and oral treatment with
fleroxacin in complicated UTI is a satisfactory treatment modality. La
rger trials should be done in a more homogeneous population, studying
shorter treatment durations in complicated UTI.